RECCE 327
Alternative Names: R 327; R-327G; RECCE-327Latest Information Update: 28 Feb 2025
At a glance
- Originator Recce Pharmaceuticals
- Developer Path BioAnalytics; Recce Pharmaceuticals
- Class Anti-infectives; Antibacterials; Antivirals; Foot disorder therapies; Polymers; Skin disorder therapies; Urinary anti-infective agents
- Mechanism of Action Bacterial protein inhibitors; Cell wall modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bacterial infections
- Phase I/II Burn infections; Diabetic foot ulcer; Urinary tract infections
- Preclinical Clostridium infections; COVID 2019 infections; Nosocomial pneumonia; Streptococcal infections; Ventilator associated pneumonia
- No development reported Influenza virus infections; Sepsis
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Bacterial-infections(In volunteers) in Australia (IV, Infusion)
- 27 Feb 2025 Recce Pharmaceuticals has patent protection for RECCE® 327 and RECCE® 529 in Japan
- 18 Feb 2025 Updated efficacy data from a phase II trial in Bacterial infection released by Recce Pharmaceuticals